MY127294A - Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments - Google Patents
Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicamentsInfo
- Publication number
- MY127294A MY127294A MYPI20022876A MYPI20022876A MY127294A MY 127294 A MY127294 A MY 127294A MY PI20022876 A MYPI20022876 A MY PI20022876A MY PI20022876 A MYPI20022876 A MY PI20022876A MY 127294 A MY127294 A MY 127294A
- Authority
- MY
- Malaysia
- Prior art keywords
- flibanserin
- relates
- preparation
- technical process
- crystalline polymorph
- Prior art date
Links
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002053 flibanserin Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108091005479 5-HT2 receptors Proteins 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000002076 thermal analysis method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118593 | 2001-08-02 | ||
| EP01130180 | 2001-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY127294A true MY127294A (en) | 2006-11-30 |
Family
ID=26076670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20022876A MY127294A (en) | 2001-08-02 | 2002-07-31 | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP1414816B1 (OSRAM) |
| JP (1) | JP3822601B2 (OSRAM) |
| KR (1) | KR100899297B1 (OSRAM) |
| CN (1) | CN1288147C (OSRAM) |
| AR (2) | AR036208A1 (OSRAM) |
| AT (1) | ATE288911T1 (OSRAM) |
| AU (1) | AU2002331361B2 (OSRAM) |
| BR (1) | BR0211601A (OSRAM) |
| CA (1) | CA2450093C (OSRAM) |
| CO (1) | CO5560572A2 (OSRAM) |
| DE (1) | DE60202958T2 (OSRAM) |
| DK (1) | DK1414816T3 (OSRAM) |
| EA (1) | EA006400B1 (OSRAM) |
| ES (1) | ES2237694T3 (OSRAM) |
| HR (1) | HRP20040107B1 (OSRAM) |
| HU (1) | HU228666B1 (OSRAM) |
| IL (2) | IL159151A0 (OSRAM) |
| MX (1) | MXPA04000913A (OSRAM) |
| MY (1) | MY127294A (OSRAM) |
| NZ (1) | NZ530510A (OSRAM) |
| PL (1) | PL210224B1 (OSRAM) |
| PT (1) | PT1414816E (OSRAM) |
| RS (1) | RS50742B (OSRAM) |
| SI (1) | SI1414816T1 (OSRAM) |
| UA (1) | UA76767C2 (OSRAM) |
| WO (1) | WO2003014079A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| DE10138273A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| NZ537253A (en) * | 2002-05-22 | 2007-09-28 | Boehringer Ingelheim Pharma | Coated pharmaceutical compositions containing flibanserin polymorph A |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| US20090247546A1 (en) * | 2006-02-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Treatment of Prevention of Valvular Heart Disease with Flibanserin |
| JP2009536176A (ja) * | 2006-05-09 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 閉経後の性的欲求障害の治療のためのフリバンセリンの使用 |
| EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| WO2008019996A2 (en) | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| JP5220746B2 (ja) | 2006-08-25 | 2013-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御放出システム及びその製造方法 |
| WO2008061966A2 (en) * | 2006-11-22 | 2008-05-29 | Boehringer Ingelheim International Gmbh | New use of flibanserin |
| US8722682B2 (en) | 2006-12-20 | 2014-05-13 | Sprout Pharmaceuticals, Inc. | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity |
| EP1955699A1 (en) * | 2007-02-08 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flibanserin for the treatment of insomnia |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| EP2090297A1 (en) | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
| CA2686480A1 (en) * | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
| CN104926734B (zh) * | 2015-07-07 | 2017-04-05 | 苏州立新制药有限公司 | 氟班色林的制备方法 |
| WO2017076356A1 (zh) * | 2015-11-05 | 2017-05-11 | 苏州晶云药物科技有限公司 | 氟班色林的新晶型及其制备方法 |
| CN108699007A (zh) * | 2016-01-31 | 2018-10-23 | 孟晓明 | 氟班色林的新晶型及其制备方法及其用途 |
| CN111303043A (zh) * | 2019-04-19 | 2020-06-19 | 武汉万知化工医药有限公司 | 一种氟班色林盐酸盐的制备方法 |
| CN115919860B (zh) * | 2022-12-05 | 2023-11-10 | 中国药科大学 | 氟班色林在制备治疗雄激素脱发药物中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
-
2002
- 2002-07-30 WO PCT/EP2002/008466 patent/WO2003014079A1/en not_active Ceased
- 2002-07-30 NZ NZ530510A patent/NZ530510A/en not_active IP Right Cessation
- 2002-07-30 DK DK02767277T patent/DK1414816T3/da active
- 2002-07-30 EA EA200400252A patent/EA006400B1/ru not_active IP Right Cessation
- 2002-07-30 EP EP02767277A patent/EP1414816B1/en not_active Expired - Lifetime
- 2002-07-30 ES ES02767277T patent/ES2237694T3/es not_active Expired - Lifetime
- 2002-07-30 SI SI200230104T patent/SI1414816T1/xx unknown
- 2002-07-30 RS YUP-78/04A patent/RS50742B/sr unknown
- 2002-07-30 JP JP2003519029A patent/JP3822601B2/ja not_active Expired - Fee Related
- 2002-07-30 EP EP04026410A patent/EP1518858A1/en not_active Withdrawn
- 2002-07-30 BR BR0211601-4A patent/BR0211601A/pt not_active Application Discontinuation
- 2002-07-30 HR HR20040107A patent/HRP20040107B1/xx not_active IP Right Cessation
- 2002-07-30 PL PL364598A patent/PL210224B1/pl unknown
- 2002-07-30 AU AU2002331361A patent/AU2002331361B2/en not_active Expired
- 2002-07-30 PT PT02767277T patent/PT1414816E/pt unknown
- 2002-07-30 CN CNB028152263A patent/CN1288147C/zh not_active Expired - Fee Related
- 2002-07-30 UA UA2004031505A patent/UA76767C2/uk unknown
- 2002-07-30 AT AT02767277T patent/ATE288911T1/de active
- 2002-07-30 DE DE60202958T patent/DE60202958T2/de not_active Expired - Lifetime
- 2002-07-30 IL IL15915102A patent/IL159151A0/xx unknown
- 2002-07-30 CA CA002450093A patent/CA2450093C/en not_active Expired - Fee Related
- 2002-07-30 HU HU0401201A patent/HU228666B1/hu unknown
- 2002-07-30 MX MXPA04000913A patent/MXPA04000913A/es active IP Right Grant
- 2002-07-30 KR KR1020047001497A patent/KR100899297B1/ko not_active Expired - Fee Related
- 2002-07-31 MY MYPI20022876A patent/MY127294A/en unknown
- 2002-08-02 AR ARP020102942A patent/AR036208A1/es not_active Application Discontinuation
-
2003
- 2003-12-02 IL IL159151A patent/IL159151A/en active IP Right Grant
-
2004
- 2004-02-25 CO CO04016766A patent/CO5560572A2/es unknown
-
2010
- 2010-07-15 AR ARP100102577A patent/AR077416A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY127294A (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
| CA2684149C (en) | Metabolites of (thio)carbamoyl-cyclohexane derivatives | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| MXPA04006004A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
| CA2243234C (en) | 5h-thiazolo[3,2-a]pyrimidine derivatives | |
| TWI254038B (en) | N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD | |
| WO2005077950A3 (en) | Medicaments with hm74a receptor activity | |
| CZ304702B6 (cs) | (4R) a (4S) diastereoizomery (2S)-2-[2-oxo-4-propylpyrrolidinyl] butanamidu, farmaceutická kompozice s jejich obsahem a jejich použití | |
| YU96502A (sh) | Derivati benzotiazola | |
| CA2455296A1 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors | |
| UY26290A1 (es) | Compuestos químicos xxi | |
| TW200800957A (en) | New compounds | |
| RU2008148325A (ru) | Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы | |
| US5985895A (en) | 2-naphthamide derivatives and their therapeutic applications | |
| TW408117B (en) | Use of N-substituted phenothiazines | |
| JP5072604B2 (ja) | １−［３−［３−（４−クロロフェニル）プロポキシ］プロピル］−ピペリジン一塩酸塩 | |
| EP4301747A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| CN101970427A (zh) | 治疗疼痛症状及其它失调的方法 | |
| JP2569088B2 (ja) | 塩基性置換フェニルアセトニトリル及びカルシウム拮抗作用を有する心血管系疾患の治療剤 | |
| WO2002066429A8 (de) | Verfahren zur herstellung von nicht hydratisiertem fexofenadin-hydrochlorid und eine so erhaetliche neue kristalline form | |
| TW593294B (en) | Polycyclic thiazole systems having anorectic activity, processes for their preparation and pharmaceutical composition comprising these compounds | |
| JPH0372061B2 (OSRAM) | ||
| JPS63255266A (ja) | 抗不整脈剤 | |
| TW200932213A (en) | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof | |
| MXPA03011193A (es) | Nuevos compuestos utiles en enfermedad de reflujo. |